Brief: Samsung Bioepis Enters Into A Partnership With Harrow For Commercialization Of Ophthalmology Biosimilars Portfolio In United States
17/07/2025 12:58
Harrow Inc HROW.O: SAMSUNG BIOEPIS ENTERS INTO A PARTNERSHIP WITH HARROW FOR COMMERCIALIZATION OF OPHTHALMOLOGY BIOSIMILARS PORTFOLIO IN UNITED STATES Source text: ID:nBw7sj5wza Further company coverage: HROW.O
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates